APM News and Press, Aptorum Group Limited From 03/02/23

APM - Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces the exciting commercial launch of NativusWell &#x...

APM - Aptorum Group regains compliance with nasdaq minimum bid price

Aptorum Group ( NASDAQ: APM ) received two notices from the Nasdaq statin it had regained compliance with the minimum bid price requirement, but does not meet the minimum market value of publicly held shares of $5M. For further details see: Aptorum Group regains compliance w...

APM - Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced t...

APM - Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced t...

APM - Aptorum Group climbs 3%, announces 1-for-10 reverse stock split

Aptorum Group ( NASDAQ: APM ) announced a 1-for-10 reverse stock split of the company's shares, effective on January 23, 2023. The shares are expected to commence trading on a split-adjusted basis when the markets open on January 23, 2023. The reverse stock split was implement...

APM - Aptorum Group Announces 1-for-10 Reverse Stock Split

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (the “Company”) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, today announced a 1-for-10 reverse stock split of the C...

APM - Andean Precious Metals Achieves 2022 Production Guidance with 5.0 Million Ounces of Silver Equivalent

Toronto, Ontario--(Newsfile Corp. - January 17, 2023) - Andean Precious Metals Corp. (TSXV: APM) (OTCQX: ANPMF) ("Andean" or the "Company") is pleased to announce that the Company has met its production guidance for 2022 with 5.0 million ounces (Moz) of silver equivalent (Ag Eq) [1] from its San...

APM - Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, is pleased to announce the recent publication of a joint effort for assessing a rapid...

APM - Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the res...

APM - Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced t...

Company Name:	Aptorum Group Limited
Stock Symbol:	APM
Market:	NASDAQ
Website:	aptorumgroup.com